Finance

Lists
BIO:NYSE
Bio-Rad Laboratories, Inc. Class A Common Stock
USD 364,90
+0,32%
(+1,17) 1D
14 Okt., 11:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BIO...
Open
USD 367,86
High
USD 371,07
Low
USD 363,47
Mkt. cap
9,76 mjd
Avg. vol.
253,41 k
Volume
17,49 k
P/E ratio
44,24
52-wk high
USD 396,23
52-wk low
USD 236,73
EPS
USD 8,25
Beta
1,07
Shares outstanding
21,68 m
No. of employees
7 k
Open
USD 367,86
High
USD 371,07
Low
USD 363,47
Mkt. cap
9,76 mjd
Avg. vol.
253,41 k
Volume
17,49 k
P/E ratio
44,24
52-wk high
USD 396,23
52-wk low
USD 236,73
EPS
USD 8,25
Beta
1,07
Shares outstanding
21,68 m
No. of employees
7 k
News stories
From web sources and news partners
Profile
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, California, by husband and wife team David and Alice Schwartz, both graduates of the University of California, Berkeley. Bio-Rad is based in Hercules, California, and has operations worldwide. Wikipedia
About Bio-Rad Laboratories, Inc. Class A Common Stock
CEONorman David Schwartz
Employees7,45 k
Founded1952
HeadquartersHercules, Kalifornië, Verenigde State van Amerika
SectorHealth care
Websitebio-rad.com
Analyst ratings
Based on 2 analysts giving stock ratings to BIO in the past 3 months
Buy
Buy
1
Hold
1
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for BIO in the last 3 months.
Highest
Current USD 364,90
USD 390,00 (+6,88%)
Average
USD 360,00 (-1,34%)
Lowest
USD 330,00 (-9,56%)
Analyst
Recommendation
Action
Price target
Projected
Date
Dan Leonard
RBC Capital
Buy
Maintained
USD 390,00
+6,9%
09/27/2026
Brandon Couillard
Wells Fargo
Hold
Reiterated
USD 330,00
-9,6%
08/05/2026
Daniel Grosslight
Citi
Hold
Maintained
USD 330,00
-9,6%
08/05/2026
Tycho Peterson
Jefferies
Hold
Maintained
USD 275,00
-24,6%
05/21/2026
Unknown Analyst
RBC Capital
Buy
Initiated
USD 320,00
-12,3%
05/14/2026
Patrick B Donnelly
Citi
Hold
Downgraded
USD 300,00
-17,8%
04/07/2026
Last report
04 Aug. 2026
Fiscal period
Q2 2026
USD 2,62 / USD 1,75
+50,13%beat
Revenue / Est. (USD)
651,00 m / 623,98 m
+4,33%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
653,00 m
693,20 m
592,10 m
651,00 m
Cost of goods sold
310,20 m
348,40 m
282,70 m
305,20 m
Cost of revenue
310,20 m
348,40 m
282,70 m
305,20 m
Research and development expenses
70,60 m
66,00 m
62,90 m
61,20 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
204,20 m
217,30 m
212,10 m
211,80 m
Operating expense
274,80 m
283,30 m
275,00 m
273,00 m
Total operating expenses
585,00 m
631,70 m
557,70 m
578,20 m
Operating income
68,00 m
61,50 m
34,40 m
72,80 m
Other non operating income
-600,00 k
-600,00 k
400,00 k
600,00 k
EBT including unusual items
-431,10 m
929,20 m
-689,80 m
542,10 m
EBT excluding unusual items
71,70 m
81,90 m
45,90 m
83,80 m
Income tax expense
-89,20 m
209,20 m
-162,70 m
170,70 m
Effective tax rate
20,69%
22,51%
23,59%
31,49%
Other operating expenses
-
-
-
-
Net income
-341,90 m
720,00 m
-527,10 m
371,40 m
Net profit margin
-52,36%
103,87%
-89,02%
57,05%
Earnings per share
2,26
2,51
1,89
2,62
Interest and investment income
13,70 m
31,00 m
21,00 m
22,30 m
Interest expense
-12,30 m
-12,10 m
-12,30 m
-12,10 m
Net interest expenses
1,40 m
18,90 m
8,70 m
10,20 m
Depreciation and amortization charges
-
-
-
-
EBITDA
112,20 m
104,00 m
75,30 m
113,90 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme